Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.47 |
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 10/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 10/20 | 0.42 |
| ▸ | WNT1 | P04628 | 3/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | TTK | P33981 | 1/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.38 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19998604 | 0.74 | ERN1 (0.56) | ERN1GSK3BDYRK1AWNT1LRRK2 | |
| SCHEMBL20488997 | 0.74 | TRPA1 (0.39) | METAP2ADORA2ALRRK2 | |
| SCHEMBL12821775 | 0.74 | DYRK1A (0.46) | METAP2GSK3BDYRK1AWNT1LRRK2 | |
| SCHEMBL16014174 | 0.73 | GSK3B (0.57) | METAP2GSK3BDYRK1ALRRK2LOXL2 | |
| SCHEMBL17809710 | 0.70 | ERN1 (0.52) | ERN1GSK3BDYRK1AWNT1CHRM1 | |
| SCHEMBL18259536 | 0.70 | ERN1 (0.51) | ERN1METAP2DYRK1ALOXL2CHRM1 | |
| SCHEMBL31291085 | 0.70 | FGFR1 (0.57) | METAP2GSK3BDYRK1ALOXL2AURKB | |
| SCHEMBL17559207 | 0.70 | FGFR1 (0.57) | METAP2GSK3BDYRK1ALOXL2AURKB | |
| SCHEMBL25176822 | 0.70 | METAP2 (0.41) | ERN1METAP2GSK3BDYRK1A | |
| SCHEMBL11577937 | 0.69 | METAP2 (0.39) | METAP2ADORA2ALRRK2MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3068389-B1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | MERCK SHARP & DOHME (US) | 2019-10-02 | — | — | EP | disclosed |
| EP-3068389-B1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | MERCK SHARP & DOHME (US) | 2019-10-02 | — | — | EP | disclosed |
| US-9809568-B2 | Compounds inhibiting leucine-rich repeat kinase enzyme activity | MERCK SHARP & DOHME CORP. (US) | 2017-11-07 | — | — | US | disclosed |
| US-9809568-B2 | Compounds inhibiting leucine-rich repeat kinase enzyme activity | MERCK SHARP & DOHME CORP. (US) | 2017-11-07 | — | — | US | disclosed |
| US-20160289207-A1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2016-10-06 | — | — | US | disclosed |
| US-20160289207-A1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2016-10-06 | — | — | US | disclosed |
| EP-3068389-A1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | Merck Sharp & Dohme Corp. (US) | 2016-09-21 | — | — | EP | disclosed |
| WO-2015073344-A1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2015-05-21 | — | — | WO | disclosed |
| WO-2015073344-A1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2015-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160289207-A1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | LRRK2, LRRC47, LIMK2 | ERN1 492/4885METAP2 1312/4885GSK3B 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.